



January 8, 2015

FOR IMMEDIATE RELEASE

Company name: Otsuka Holdings Co., Ltd.
 Representative name: Tatsuo Higuchi
President and Representative Director, CEO
 Stock ticker: 4578, Tokyo Stock Exchange, First Section
 Contact: Yuji Kogure
Director, Investor Relations Department
 Telephone: +81-3-6361-7411

Terminations of Otsuka’s Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine For Pancreatic Cancer and Otsuka’s Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, OTS102

Otsuka Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Otsuka Holdings Co. Ltd., announces as follows.

Tokyo, Japan – January 8, 2015 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announces that the exclusive licensing contract that has been in effect with OncoTherapy Science, Inc. (OTS) for the development, manufacture, and marketing of a peptide therapeutic vaccine for the treatment of pancreatic cancer, will be allowed to expire, following 180-day prior notification, at the scheduled end date of the contract period. A sublicensing contract which has been in effect with Fuso Pharmaceutical Industries, Ltd. for the manufacture and marketing in Japan of OTS102, a therapeutic vaccine, will also be allowed to expire on the same date.

Otsuka will continue its efforts in oncology as a priority area. This will include the development of the peptide therapeutic vaccine OCV-C02, for which a phase 1 clinical study is currently underway in colon cancer based on a contract with OTS.